Study finds common breast cancer treatments may speed aging process

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery do not predict who will benefit more from adding hormone therapy to postoperative radiation, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

August 14, 2026

Vol.52 No.32

In Brief

Alastair Thompson to lead IU’s breast cancer center

Alastair Thompson was named director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center’s Vera Bradley Foundation Center for Breast Cancer Research.

August 07, 2026

Vol.52 No.31

In Brief

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA and an investigator at the UCLA Health Jonsson Comprehensive Cancer Center, and her research team have received a five-year, $3.9 million grant from NCI to develop drug-based strategies that could enhance cancer immunotherapy for patients with melanoma and potentially other types of cancer.

August 07, 2026

Vol.52 No.31

Clinical Roundup

BRCA-negative patients may still be high-risk for breast cancer, study finds

Women who test negative for BRCA gene mutations may still be at greater risk of developing breast cancer than the general population, according to a study led by investigators at Cedars-Sinai Medical Center, the University of Toronto, and the University of Sydney.

August 07, 2026

Vol.52 No.31

Clinical Roundup

Anti-Müllerian hormone may help many women with HR+ breast cancer avoid chemotherapy

Researchers at the University of Kansas Cancer Center, Emory University School of Medicine, and the international Southwest Oncology Group Cancer Research Network have identified a blood biomarker that may help thousands of women with hormone receptor-positive breast cancer avoid unnecessary chemotherapy.

August 07, 2026

Vol.52 No.31

Cancer Policy

NBCC’s open letter to Ways and Means demands markup for Metastatic Breast Cancer Access to Care Act

NBCC President Fran Visco authored the following open letter to the House Ways and Means Committee, criticizing the committee for failing to bring the Metastatic Breast Cancer Access to Care Act, HR 2048, before the committee for markup.

July 24, 2026

Vol.52 No.29

By Jacquelyn Cobb

Study finds common breast cancer treatments may speed aging process

YOU MAY BE INTERESTED IN

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Alastair Thompson to lead IU’s breast cancer center

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

BRCA-negative patients may still be high-risk for breast cancer, study finds

Anti-Müllerian hormone may help many women with HR+ breast cancer avoid chemotherapy

NBCC’s open letter to Ways and Means demands markup for Metastatic Breast Cancer Access to Care Act

Renew today!

Subscriber content

Never miss an issue!

Login